RNAi modulation of ApoB and uses thereof
View Patent ↗The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
1. An isolated iRNA agent comprising a sense strand and an antisense strand, wherein the agent is targeted to at least 15 contiguous nucleotides of the target sequence of AL-DUP 5098 (SEQ ID NO:155 and SEQ ID NO:156) within the ApoB mRNA, and wherein each strand is between 15 and 30 nucleotides in length.
2. The iRNA agent of claim 1 , further comprising a non-nucleotide moiety.
3. The iRNA agent of claim 1 , further comprising a phosphorothioate linkage.
4. The iRNA agent of claim 3 , wherein said iRNA agent comprises a phosphorothioate at the first and second internucleotide linkage at the 3′ end of the antisense strand.
5. The iRNA agent of claim 3 , wherein said iRNA agent comprises a phosphorothioate at the first internucleotide linkage at the 3′ end of the sense strand.
6. The iRNA agent of claim 1 , further comprising a 2′-modified nucleotide.
7. The iRNA agent of claim 6 , wherein the2′-modification is chosen from the group of: 2′-deoxy, 2′-deoxy-2′-fluoro, 2′-O-methyl, 2′-O-methoxyethyl (2′-O-MOE), 2′-0-aminopropyl (2′-O-AP), 2′-0-dimethylaminoethyl (2′-O-DMAOE), 2′-dimethylaminopropyl (2′-O-DMAP), 2′-O-dimethylaminoethyloxyethyl (2′-O-DMAEOE), and 2′-O—N-methylacetamido (2′-O-NMA).
8. The iRNA agent of claim 6 , further comprising: at least one 5′-uridine-adenine-3′ (5′-UA-3′) dinucleotide wherein the uridine is a 2′-modified nucleotide; at least one 5′-uridine-guanine-3′ (5′-UG-3′) dinucleotide, wherein the 5′-uridine is a 2′-modified nucleotide; at least one 5′-cytidine-adenine-3′ (5′-CA-3′) dinucleotide, wherein the 5′-cytidine is a 2′-modified nucleotide; or at least one 5′-uridine-uridine-3′ (5′-UU-3′) dinucleotide, wherein the 5′-uridine is a 2′-modified nucleotide.
9. The iRNA agent of claim 8 , wherein the 5′-most pyrimidines in all occurrences of sequence motif 5′-UA-3′, 5′-CA-3′, 5′-UU-3′, and 5′-UG-3′ on the antisense strand are 2′-modified nucleotides.
10. The iRNA agent of claim 1 , wherein the sense strand comprises at least 15 contiguous nucleotides of the nucleotide sequence set forth in SEQ ID NO: 155.
11. The iRNA agent of claim 1 , wherein the antisense strand comprises at least 15 contiguous nucleotides of the nucleotide sequence set forth in SEQ ID NO: 156.
12. The iRNA agent of claim 1 , wherein a 5′-end of said iRNA agent comprises an adenosine, cytidine, guanosine, thymidine, or uridine.
13. The iRNA agent of claim 1 , further comprising a nucleotide overhang having 1 to 4 nucleotides.
14. The iRNA agent of claim 13 , wherein the nucleotide overhang has 2 or 3 unpaired nucleotides.
15. The iRNA agent of claim 13 , wherein the nucleotide overhang is at the 3′-end of the antisense strand of the iRNA agent.
16. The iRNA agent of claim 1 , further comprising a cholesterol moiety.
17. The iRNA agent of claim 16 , wherein the cholesterol moiety is conjugated to the 3′-end of the sense strand of the iRNA agent.
18. The iRNA agent of claim 1 , wherein said iRNA agent reduces the amount of ApoB mRNA present in cultured mouse cells of hepatic origin by an amount greater than a control iRNA agent.
19. The iRNA agent of claim 1 , wherein the agent reduces the amount of ApoB mRNA in cultured human HepG2 cells after incubation with the agent by more than 50% compared to cells that have not been incubated with the agent, or reduces the amount of ApoB protein secreted into cell culture supernatant by more than 50% compared to a control.
20. A method for reducing the expression levels of ApoB in a subject, further comprising the step of administering the iRNA agent of claim 1 to said subject.
21. The iRNA agent of claim 6 , wherein the agent comprises a sense strand with at least 15 contiguous nucleotides of SEQ ID NO: 258 and an antisense strand with at least 15 contiguous nucleotides of SEQ ID NO: 257.